TY - JOUR
T1 - Initial disease course and treatment in an inflammatory bowel disease inception cohort in Europe
T2 - The ECCO-EpiCom cohort
AU - Burisch, Johan
AU - Pedersen, Natalia
AU - Cukovic-Cavka, Silvja
AU - Turk, Niksa
AU - Kaimakliotis, Ioannis
AU - Duricova, Dana
AU - Shonová, Olga
AU - Vind, Ida
AU - Avnstrøm, Søren
AU - Thorsgaard, Niels
AU - Krabbe, Susanne
AU - Andersen, Vibeke
AU - Jens, Frederik Dahlerup
AU - Kjeldsen, Jens
AU - Salupere, Riina
AU - Olsen, Jóngerd
AU - Nielsen, Kári Rubek
AU - Manninen, Pia
AU - Collin, Pekka
AU - Katsanos, Konstantinnos H.
AU - Tsianos, Epameinondas V.
AU - Ladefoged, Karin
AU - Lakatos, Laszlo
AU - Bailey, Yvonne
AU - O'Morain, Colm
AU - Schwartz, Doron
AU - Odes, Selwyn
AU - Martinato, Matteo
AU - Lombardini, Silvia
AU - Jonaitis, Laimas
AU - Kupcinskas, Limas
AU - Turcan, Svetlana
AU - Barros, Louisa
AU - Magro, Fernando
AU - Lazar, Daniela
AU - Goldis, Adrian
AU - Nikulina, Inna
AU - Belousova, Elena
AU - Fernandez, Alberto
AU - Hernandez, Vicent
AU - Almer, Sven
AU - Zhulina, Yaroslava
AU - Halfvarson, Jonas
AU - Tsai, Her Hsin
AU - Sebastian, Shaji
AU - Lakatos, Peter Laszlo
AU - Langholz, Ebbe
AU - Munkholm, Pia
PY - 2014/1/1
Y1 - 2014/1/1
N2 - Background: The EpiCom cohort is a prospective, population-based, inception cohort of inflammatory bowel disease (IBD) patients from 31 European centers covering a background population of 10.1 million. The aim of this study was to assess the 1-year outcome in the EpiCom cohort. Methods: Patients were followed-up every third month during the first 12 (±3) months, and clinical data, demographics, disease activity, medical therapy, surgery, cancers, and deaths were collected and entered in a Web-based database (www.epicom-ecco.eu). Results: In total, 1367 patients were included in the 1-year follow-up. In western Europe, 65 Crohn's disease (CD) (16%), 20 ulcerative colitis (UC) (4%), and 4 IBD unclassified (4%) patients underwent surgery, and in eastern Europe, 12 CD (12%) and 2 UC (1%) patients underwent surgery. Eightyone CD (20%), 80 UC (14%), and 13 (9%) IBD unclassified patients were hospitalized in western Europe compared with 17 CD (16%) and 12 UC (8%) patients in eastern Europe. The cumulative probability of receiving immunomodulators was 57% for CD in western (median time to treatment 2 months) and 44% (1 month) in eastern Europe, and 21% (5 months) and 5% (6 months) for biological therapy, respectively. For UC patients, the cumulative probability was 22% (4 months) and 15% (3 months) for immunomodulators and 6% (3 months) and 1% (12 months) for biological therapy, respectively in the western and eastern Europe. Discussion: In this cohort, immunological therapy was initiated within the first months of disease. Surgery and hospitalization rates did not differ between patients from eastern and western Europe, although more western European patients received biological agents and were comparable to previous population-based inception cohorts.
AB - Background: The EpiCom cohort is a prospective, population-based, inception cohort of inflammatory bowel disease (IBD) patients from 31 European centers covering a background population of 10.1 million. The aim of this study was to assess the 1-year outcome in the EpiCom cohort. Methods: Patients were followed-up every third month during the first 12 (±3) months, and clinical data, demographics, disease activity, medical therapy, surgery, cancers, and deaths were collected and entered in a Web-based database (www.epicom-ecco.eu). Results: In total, 1367 patients were included in the 1-year follow-up. In western Europe, 65 Crohn's disease (CD) (16%), 20 ulcerative colitis (UC) (4%), and 4 IBD unclassified (4%) patients underwent surgery, and in eastern Europe, 12 CD (12%) and 2 UC (1%) patients underwent surgery. Eightyone CD (20%), 80 UC (14%), and 13 (9%) IBD unclassified patients were hospitalized in western Europe compared with 17 CD (16%) and 12 UC (8%) patients in eastern Europe. The cumulative probability of receiving immunomodulators was 57% for CD in western (median time to treatment 2 months) and 44% (1 month) in eastern Europe, and 21% (5 months) and 5% (6 months) for biological therapy, respectively. For UC patients, the cumulative probability was 22% (4 months) and 15% (3 months) for immunomodulators and 6% (3 months) and 1% (12 months) for biological therapy, respectively in the western and eastern Europe. Discussion: In this cohort, immunological therapy was initiated within the first months of disease. Surgery and hospitalization rates did not differ between patients from eastern and western Europe, although more western European patients received biological agents and were comparable to previous population-based inception cohorts.
KW - Crohn's disease
KW - Epidemiology
KW - Outcomes research
KW - Ulcerative colitis
UR - http://www.scopus.com/inward/record.url?scp=84893671655&partnerID=8YFLogxK
U2 - 10.1097/01.MIB.0000436277.13917.c4
DO - 10.1097/01.MIB.0000436277.13917.c4
M3 - Article
C2 - 24252978
AN - SCOPUS:84893671655
SN - 1078-0998
VL - 20
SP - 36
EP - 46
JO - Inflammatory Bowel Diseases
JF - Inflammatory Bowel Diseases
IS - 1
ER -
